Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Generating realistic scaled complex networks.

Staudt CL, Hamann M, Gutfraind A, Safro I, Meyerhenke H.

Appl Netw Sci. 2017;2(1):36. doi: 10.1007/s41109-017-0054-z. Epub 2017 Oct 13.

PMID:
30533515
2.

Integrating evidence, models and maps to enhance Chagas disease vector surveillance.

Gutfraind A, Peterson JK, Billig Rose E, Arevalo-Nieto C, Sheen J, Condori-Luna GF, Tankasala N, Castillo-Neyra R, Condori-Pino C, Anand P, Naquira-Velarde C, Levy MZ.

PLoS Negl Trop Dis. 2018 Nov 29;12(11):e0006883. doi: 10.1371/journal.pntd.0006883. eCollection 2018 Nov.

3.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

PMID:
29997251
4.

High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.

Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H.

J Urban Health. 2018 Feb;95(1):71-82. doi: 10.1007/s11524-017-0185-7.

PMID:
28875410
5.

Operational resilience: concepts, design and analysis.

Ganin AA, Massaro E, Gutfraind A, Steen N, Keisler JM, Kott A, Mangoubi R, Linkov I.

Sci Rep. 2016 Jan 19;6:19540. doi: 10.1038/srep19540.

6.

Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.

Fu R, Gutfraind A, Brandeau ML.

Math Biosci. 2016 Mar;273:102-13. doi: 10.1016/j.mbs.2016.01.003. Epub 2016 Jan 14.

7.

Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections.

Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME.

PLoS One. 2015 Sep 30;10(9):e0137993. doi: 10.1371/journal.pone.0137993. eCollection 2015.

8.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.

9.

Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Gutfraind A, Galvani AP, Meyers LA.

JAMA Pediatr. 2015 Apr;169(4):341-8. doi: 10.1001/jamapediatrics.2014.3804.

10.

Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.

Gutfraind A, Meyers LA.

J Infect Dis. 2015 Apr 15;211(8):1262-7. doi: 10.1093/infdis/jiv042. Epub 2015 Jan 29.

11.

Optimizing distribution of pandemic influenza antiviral drugs.

Singh B, Huang HC, Morton DP, Johnson GP, Gutfraind A, Galvani AP, Clements B, Meyers LA.

Emerg Infect Dis. 2015 Feb;21(2):251-8. doi: 10.3201/eid2102.141024.

12.

Evader Interdiction: Algorithms, Complexity and Collateral Damage.

Johnson MP, Gutfraind A, Ahmadizadeh K.

Ann Oper Res. 2014 Nov 1;222(1):341-359.

13.

Optimizing topological cascade resilience based on the structure of terrorist networks.

Gutfraind A.

PLoS One. 2010 Nov 10;5(11):e13448. doi: 10.1371/journal.pone.0013448.

14.

Error-reducing structure of the genetic code indicates code origin in non-thermophile organisms.

Gutfraind A, Kempf A.

Orig Life Evol Biosph. 2008 Feb;38(1):75-85. Epub 2007 Jun 7.

PMID:
17554636

Supplemental Content

Loading ...
Support Center